4//SEC Filing
Avoro Capital Advisors LLC 4
Accession 0000902664-21-004071
CIK 0001422142other
Filed
Aug 29, 8:00 PM ET
Accepted
Aug 30, 7:39 PM ET
Size
13.3 KB
Accession
0000902664-21-004071
Insider Transaction Report
Form 4
Avoro Capital Advisors LLC
Director10% OwnerOther
Transactions
- Award
Common Stock, $0.0001 par value per share ("Common Stock")
2021-08-26$13.08/sh+1,911,752$24,999,981→ 2,211,752 total(indirect: See footnotes) - Award
Stock option (right to buy)
2021-08-27+17,549→ 17,549 totalExercise: $26.00Exp: 2031-08-27→ Common Stock (17,549 underlying)
Avoro Ventures LLC
Director10% OwnerOther
Transactions
- Award
Common Stock, $0.0001 par value per share ("Common Stock")
2021-08-26$13.08/sh+1,911,752$24,999,981→ 2,211,752 total(indirect: See footnotes) - Award
Stock option (right to buy)
2021-08-27+17,549→ 17,549 totalExercise: $26.00Exp: 2031-08-27→ Common Stock (17,549 underlying)
Aghazadeh Behzad
Director10% OwnerOther
Transactions
- Award
Stock option (right to buy)
2021-08-27+17,549→ 17,549 totalExercise: $26.00Exp: 2031-08-27→ Common Stock (17,549 underlying) - Award
Common Stock, $0.0001 par value per share ("Common Stock")
2021-08-26$13.08/sh+1,911,752$24,999,981→ 2,211,752 total(indirect: See footnotes)
Footnotes (4)
- [F1]This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
- [F2]The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
- [F3]The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors and Avoro Ventures directly from the Issuer in a PIPE financing completed in connection with the closing of the Agreement and Plan of Merger between the Issuer and Aadi Bioscience, Inc., dated as of May 16, 2021, following which the Issuer changed its name to Aadi Bioscience, Inc.
- [F4]In connection with the closing of the Merger, as approved by the stockholders of the Issuer on August 17, 2021, the Board granted on August 26, 2021 to the Reporting Person an Initial Award (as defined in the Issuer's Outside Director Compensation Policy and in accordance with the Issuer's 2021 Equity Incentive Plan (the "Plan")). Subject to the Reporting Person continuing to be a Service Provider (as defined in the Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021.
Documents
Issuer
Aadi Bioscience, Inc.
CIK 0001422142
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001633313
Filing Metadata
- Form type
- 4
- Filed
- Aug 29, 8:00 PM ET
- Accepted
- Aug 30, 7:39 PM ET
- Size
- 13.3 KB